Jim Simons Context Therapeutics Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Context Therapeutics Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 66,000 shares of CNTX stock, worth $67,320. This represents 0.0% of its overall portfolio holdings.

Number of Shares

66,000

Previous 65,200 1.23%

Holding current value

$67,320

Previous $130,000 0.77%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.79 - $2.66 $1,432 - $2,128	800 Added 1.23%	66,000 $129,000
Q2 2024 Aug 09, 2024	BUY	$1.24 - $2.19 $31,372 - $55,407	25,300 Added 63.41%	65,200 $130,000
Q1 2024 May 13, 2024	BUY	$0.92 - $1.38 $7,084 - $10,626	7,700 Added 23.91%	39,900 $55,000
Q4 2023 Feb 13, 2024	BUY	$0.79 - $1.41 $1,659 - $2,961	2,100 Added 6.98%	32,200 $36,000
Q3 2023 Nov 14, 2023	BUY	$0.9 - $1.59 $1,620 - $2,862	1,800 Added 6.36%	30,100 $45,000
Q2 2023 Aug 11, 2023	BUY	$0.48 - $1.6 $4,368 - $14,560	9,100 Added 47.4%	28,300 $45,000
Q1 2023 May 12, 2023	SELL	$0.56 - $1.06 $48,216 - $91,266	-86,100 Reduced 81.77%	19,200 $11,000
Q4 2022 Feb 13, 2023	SELL	$0.61 - $1.42 $15,425 - $35,908	-25,288 Reduced 19.36%	105,300 $69,000
Q3 2022 Nov 14, 2022	BUY	$1.11 - $2.08 $144,952 - $271,623	130,588 New	130,588 $145,000
Q2 2022 Aug 12, 2022	SELL	$1.29 - $2.66 $26,198 - $54,021	-20,309 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.72 - $2.82 $76,211 - $124,951	-44,309 Reduced 68.57%	20,309 $44,000
Q4 2021 Feb 11, 2022	BUY	$2.66 - $7.45 $171,883 - $481,404	64,618 New	64,618 $172,000

Others Institutions Holding CNTX

# of Institutions

Shares Held

56.9M

Call Options Held

Put Options Held

View Full List

About Context Therapeutics Inc.

Ticker CNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,966,100
Market Cap $16.3M
Description
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therape...

More about CNTX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account